...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life Science Journal >23-gauge microincision total vitrectomy without anti-vascular endothelial growth factor treats proliferative diabetic retinopathy Short title: 23-gauge microincision total vitrectomy without anti-VEGF treats PDR
【24h】

23-gauge microincision total vitrectomy without anti-vascular endothelial growth factor treats proliferative diabetic retinopathy Short title: 23-gauge microincision total vitrectomy without anti-VEGF treats PDR

机译：不用抗血管内皮生长因子的23号显微切口全玻璃体切除术治疗增生性糖尿病视网膜病变简短标题：不使用抗VEGF的23号显微切口全玻璃体切除术治疗PDR

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To explore how to treat proliferative diabetic retinopathy (PDR) with 23-gauge microincision total vitrectomy (23G MTV) and how to prevent intraocular bleeding with methods beyond anti-vascular endothelial growth factor (anti-VEGF) drugs. Methods: This was a Retrospective case cohort series study of patients who received 23G MTV for the treatment of PDR. All operations were carried out by one vitreoretinal surgeon. The anti-bleeding management were used except anti-VEGF injection. The follow-up period was 10.25 ± 2.29 months. Pre-/past-operative IOP and best corrected visual acuity（BCVA）were measured and statistically compared. Results: All patients had no application of anti-VEGF drugs before and after operations. Introperatively, the active bleeding was stopped by increasing intraocular pressure in 5 eyes and by using cutter compression in 3 eyes. These methods successfully stop all bleeding. The rest of 42 eyes had no obvious bleeding during operation and follow-up time. No retinal detachment happened in these patients. They had improved visual acuity (χ2=34.69，Pt = -1.228，P= 0.228). Conclusion: 23G MTV is a feasible and safe treatment for proliferative diabetic retinopathy,Intraocular hemorrhage during and after the operation may be avoided without anti-VEGF injection.
机译：目的：探讨用23号微切口全玻璃体切除术（23G MTV）治疗增生性糖尿病视网膜病变（PDR）的方法，以及如何通过抗血管内皮生长因子（anti-VEGF）药物以外的方法预防眼内出血。方法：这是一项回顾性病例队列研究，研究对象是接受23G MTV治疗PDR的患者。所有手术均由一名玻璃体视网膜外科医生进行。除抗VEGF注射外，使用抗出血管理。随访时间为10.25±2.29个月。测量术前/术后IOP和最佳矫正视力（BCVA）并进行统计学比较。结果：所有患者在手术前后均未应用抗VEGF药物。术中，通过增加5只眼的眼内压和使用3只眼的切刀加压来停止活动性出血。这些方法成功地阻止了所有出血。其余42只眼在手术和随访期间均无明显出血。这些患者未发生视网膜脱离。他们的视力得到了改善（χ2= 34.69，Pt = -1.228，P = 0.228）。结论：23G MTV是治疗糖尿病性增生性视网膜病变的一种可行，安全的方法，无需注射抗VEGF即可避免术中和术后眼内出血。

著录项

  • 来源
    《Life Science Journal》 |2015年第4期|共6页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号